FDA Approved · Holter Monitor

HiCardi+ H100

An advanced, wearable cardiac monitor designed to address the limitations of traditional Holter monitors. A compact, adhesive patch placed on the chest that continuously records ECG data for up to 3 days.

Wearable ECG Patch Up to 72 Hours IP67 Waterproof

Arrhythmia types detected

18 g

Featherweight on-body

72 h

Continuous recording

~100 min

Full recharge time

HiCardi+ H100 wireless Holter monitor with charging cradle on a desk

Key Features

Why HiCardi+ H100

Built around the limitations of conventional Holter — uncomfortable wiring, restricted activity, short recording windows. The H100 delivers continuous, clinical-grade ECG data without disrupting daily life.

Continuous ECG Recording

Records uninterrupted data over a longer period, increasing the likelihood of detecting intermittent arrhythmias.

Comfort & Convenience

Lightweight, wireless design lets patients carry out normal daily activities — including showering.

Accurate Diagnosis

Continuous, high-quality data provides a comprehensive view of the heart's activity for clinician review.

Patient-Friendly

Comfortable, non-invasive adhesive patch — easy to wear, improving compliance and overall patient experience.

Specifications

Technical Specifications

Manufactured by Mezoo, Republic of Korea. Holds FDA approval and meets international medical safety standards.

Device

ManufacturerMezoo — Republic of Korea

Dimensions60 × 40 × 10 mm (W×L×T)

Weight18 g

Ingress ProtectionIP67 Waterproof (shower-safe)

Operating TimeUp to 72 hours

Recharge TimeApproximately 100 minutes

AttachmentWireless SmartPatch with disposable electrodes

Regulatory

FDAApproved

InternationalMeets medical safety standards

AKL (Indonesia)20502520483

Local DistributorPT Tangan Ibu Medis

Joint OperationRSJPD Harapan Kita — 10-year agreement

HiCardi+ H100 size comparison: 35.58 mm tall, next to a 26.5 mm coin

A compact Holter ECG device — small in size, big in capability. (35.58 mm tall, compared to a ₩500 coin)

Detection

14 Arrhythmia Types Detected

The H100's continuous data combined with automated analysis flags 14 distinct arrhythmia patterns for clinician verification.

Pause

Premature Ventricular Contraction

Ventricular Bigeminy

Ventricular Trigeminy

Couplet

Triplet

Sinus Bradycardia

Sinus Tachycardia

Atrial Tachycardia

Supra-Ventricular Tachycardia

Ventricular Tachycardia

Ventricular Flutter / Fibrillation

Atrial Fibrillation

Paced Rhythm

Workflow

End-to-End Diagnostic Workflow

From device fitting to AI-assisted analysis and cardiologist verification — H100 supports a three-phase clinical workflow integrated with the LiveStudio platform.

Three-phase HiCardi+ H100 diagnostic workflow: Patient initiation, Data return & upload, AI scan & expert verification

Phase 1: hospital attaches the device (24/48/72 h). Phase 2: device returned, data uploaded via HiCardi Sync to LiveStudio. Phase 3: built-in AI provides initial interpretation, followed by cardiologist verification.

Market Context

Why HiCardi for the Indonesian Market

Cardiovascular disease accounts for more than 200,000 deaths annually in Indonesia (≈ 14.38% of total mortality), with coronary heart disease making up nearly half of all cardiovascular cases. Prevalence has increased 10.5% over the past 20 years, with recent surge in patients aged 25–34.

Cardiovascular health data for Indonesia 2025: 284 million population, 14.38% mortality from CVD, regional hotspots in DI Yogyakarta, Papua Tengah, DKI Jakarta

Indonesia presents a strong potential market for HiCardi: 200,000+ annual CVD deaths, 10.5% rising prevalence, and concentrated regional hotspots requiring accessible, continuous heart monitoring.